Esperion Therapeutics Inc. (ESPR)
NASDAQ · Healthcare
Esperion Therapeutics Inc. Operating Income 2018–2025
Esperion Therapeutics Inc. annual/quarterly operating income history and growth rate from 2018 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Esperion Therapeutics Inc. operating income for the quarter ending March 31, 2026 was -6.6 M, a 70.22% decrease year-over-year.
- Esperion Therapeutics Inc. operating income for the twelve months ending March 31, 2026 was -31.5 M, a 200.81% decrease year-over-year.
- Esperion Therapeutics Inc. annual operating income for 2025 was 60.3 M, a 10.79% increase from 2024.
- Esperion Therapeutics Inc. annual operating income for 2024 was 54.4 M, a 134.97% decrease from 2023.
- Esperion Therapeutics Inc. annual operating income for 2023 was -155.6 M, a 13.34% decrease from 2022.
- Esperion Therapeutics Inc. annual operating income for 2022 was -179.5 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Esperion Therapeutics Inc. Operating Income — FAQ
Esperion Therapeutics Inc. (ESPR) operating income over the last 8 years — annual and quarterly figures with year-over-year growth and charts.
What is Esperion Therapeutics Inc.'s operating income?
Esperion Therapeutics Inc. (ESPR) reported operating income of $60M for fiscal 2025.
Where can I see ESPR's operating income history?
The chart and table above show Esperion Therapeutics Inc.'s operating income by year and by quarter, including the growth rate.